27 Results

Phase III INVICTUS study results positive for ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors

 Added 1 month ago

Deciphera Pharmaceuticals, Inc. announced positive top-line data from the INVICTUS pivotal Phase III clinical study of ripretinib, a broad-spectrum KIT...

FDA accepts filing of BLU 285 for Exon 18 mutant gastrointestinal stromal tumours

 Added 1 month ago

Blueprint Medicines announced that the FDA has accepted the company's New Drug Application (NDA) for BLU 285 (avapritinib) for the treatment of adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST).

Updated data from registration enabling NAVIGATOR trial of avapritinib for patients with PDGFRalpha, D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. Blueprint Medicines

 Added 10 months ago

Blueprint Medicines Corporation announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT...

Blueprint Medicines initiates Phase III trial of avapritinib to treat patients with advanced GIST.

 Added 1 year ago

Blueprint Medicines has dosed the first patient in the VOYAGER Phase III clinical trial, which is evaluating the safety and...

Induced pluripotent stem cells – a potential cancer vaccine

 Added 1 year ago

Induced pluripotent stem cells – a potential cancer vaccine

A new study from Stanford University may have found another use for iPS cells: priming the immune system to attack tumours.

World Cancer Day 2018

 Added 1 year ago

World Cancer Day 2018

UK NICE recommends use of Stivarga (regorafenib) in adults with gastrointestinal stromal tumours.- Bayer HealthCare.

 Added 1 year ago

The UK National Institute for Health and Care Excellence has backed Stivarga (regorafenib), from Bayer Healthcare, as a cost-effective option...

Load more